Selective inhibition of the inducible nitric oxide synthase by aminoguanidine

https://doi.org/10.1016/0014-2999(93)90357-NGet rights and content

Abstract

Overproduction of the free radical nitric oxide (NO) has been implicated in the pathogenesis of a variety of inflammatory and immunologically mediated diseases as well as complications of diabetes. In the present study we have demonstrated that aminoguanidine selectively inhibits the cytokine-inducible isoform of NO synthase which appears to be responsible for the excess production of NO linked to these disease states. By using organ, cell and enzyme-based measurements we have shown that aminoguanidine is equipotent to NG-monomethyl-L-arginine (L-NMA) as an inhibitor of the cytokine-induced isoform of NO synthase but is 10 to 100-fold less potent as an inhibitor of the constitutive isoform. Thus, aminoguanidine may be useful as a selective inhibitor of the inducible NO synthase in the treatment of disease states characterized by the pathological overproduction of NO.

References (32)

  • D.S. Bredt et al.

    Nitric oxide mediates glutamate-linked enhancement of cGMP levels in the cerebellum

  • D.S. Bredt et al.

    Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme

  • J.A. Corbett et al.

    Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction

    Diabetes

    (1992)
  • R.F. Furchgott et al.

    The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine

    Nature

    (1980)
  • J. Garthwaite et al.

    Endothelium-derived relaxing factor release on activation of NMDA receptors suggests role as intercellular messenger in the brain

    Nature

    (1988)
  • J.B. Hibbs et al.

    Macrophage cytotoxicity: role for L-arginine deminase activity and imino nitrogen oxidation to nitrite

    Science

    (1987)
  • Cited by (0)

    View full text